Effect of Antihypertensive Medication Adherence among Employees with Hypertension

American Journal of Managed Care

Volumn 15, Issue 12, 2009, Pages 871-880

  Lynch, Wendy D ^a   Markosyan, Karine ^a   Melkonian, Arthur K ^a   Pesa, Jacqueline ^b   Kleinman, Nathan L ^a  

^a Human Capital Management Services   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ABSENTEEISM; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BILLING AND CLAIMS; COMORBIDITY; DATA BASE; DEMOGRAPHY; DISABILITY; DRUG COST; EMPLOYEE; EMPLOYER; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; OCCUPATIONAL HEALTH; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTIHYPERTENSIVE AGENTS; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 74049092354     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. American Heart Association. Heart Disease & Stroke Statistics: 2009 Update At-a-Glance. Dallas, TX: American Heart Association; 2009. http://www.americanheart.org/downloadableheart/1240250946756L S-1982%20Heart%20and%20Stroke%20Update.042009.pdf. Accessed July 27, 2009.
2. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44(4):398-404.
3. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290(7):891-897.
4. Levy D, Larson MG. Vasan RS, Kannel WB, Ho KK.The progression from hypertension to congestive heart failure. JAMA. 1996;275(20): 1557-1562.
5. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens Suppl. 1994;12(10):S5-S14.
6. Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care. 2001;39(6):599-615.
7. American Heart Association. High blood pressure statistics, http:// www.americanheart.org/presenter.jhtml?identifier=4621. Accessed October 10, 2008.
8. Eaddy MT, Shah M, Lunacsek O, Stanford RH. The burden of illness of hypertension and comorbid diabetes. Curr Med Res Opin. 2008;24(9):2501-2507.
9. National Heart, Lung, and Blood Institute. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Institutes of Health; 1997. NIH publication 98-4080 ed. http://www.ncbi.nlm.nih. gov/books/bv.fcgi?rid=hbp. Accessed October 10, 2008.
10. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12(11 ):678-683.
11. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827-838.
12. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the SwedishTrial in Old Patients With Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281-1285.
13. Ambrosioni E. Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmacoeconomics. 2001;19(4):337-347.
14. Elliott WJ. The economic impact of hypertension. J Clin Hypertens (Greenwich). 2003;5(3 suppl 2):3-13.
15. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534-2544.
16. MacMahon S, Neal B, Rodgers A, Chalmers J. The PROGRESS trial three years later: time for more action, less distraction [published correction appears in BMJ. 2004;329(7474):1073]. BMJ. 2004;329(7472):970-971.
17. Degli Esposti L, Valpiani G. Pharmacoeconomic burden of undertreating hypertension. Pharmacoeconomics. 2004;22(14):907-928.
18. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
19. Ambrosioni E. Pharmacoeconomic challenges in disease management of hypertension. J Hypertens Suppl. 2001;19(3):S33-S40.
20. Mar J, Rodríguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens. 2001;19(1):149-155.
21. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care. 1994;32(3):214-226.
22. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther. 1997;19(6):1446-1457, 1424-1425.
23. Nichol MB, Venturini F, Sung JC. A critical evaluation of the meth-odology of the literature on medication compliance. Ann Pharmacother. 1999;33(5):531-540.
24. Schlenk EA, Burke LE, Rand C. Behavioral strategies to improve medication-taking compliance. In: Burke LE, Ockene IS, eds. Compliance in Healthcare and Research. Armonk, NY: Futura Publishing Co; 2001:57-70.
25. Jokisalo E, Enlund H, Halonen P, Takala J, Kumpusalo E. Factors related to poor control of blood pressure with antihypertensive drug therapy. Blood Press. 2003;12(1):49-55.
26. Brunenberg DE, Wetzels GE, Nelemans PJ, et al. Cost effectiveness of an adherence-improving programme in hypertensive patients. Pharmacoeconomics. 2007;25(3):239-251.
27. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997;102(2A):43-49.
28. Groban MD, Evans RM, Edgren B, et al. Clinical benefits and cost reduction associated with a comprehensive asthma management programme at a managed care organisation. Dis Manag Health Outcomes. 1998;4:93-100.
29. Thompson D, Hylan TR, McMullen W, Romeis ME, Buesching D, Oster G. Predictors of a medical-offset effect among patients receiving antidepressant therapy. Am J Psychiatry. 1998;155(6):824-827.
30. McCulloch D. Managing diabetes for improved health and economic outcomes. Am J Manag Care. 2000;6(21 suppl):S1089-S1095.
31. Balkrishnan R, Christensen DB, Bowton DL. Self-reported health status, prophylactic medication use, and healthcare costs in older adults with asthma. J Am Geriatr Soc. 2002;50(5):924-929.
32. Soumerai SB, Avom J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med. 1987;317(9):550-556.
33. Soumerai SB, Lipton HL. Computer-based drug-utilization review: risk, benefit, or boondoggle? N Engl J Med. 1995;332(24):1641-1645.
34. Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Millwood). 1999;18(2):201-212.
35. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421-429.
36. Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The health effects of restricting prescription medication use because of cost. Med Care. 2004;42(7):626-634.
37. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290(2):197]. JAMA. 2003;289(19):2560-2572.